Showing 1 - 20 results of 27 for search 'Jorge E. Cortes', query time: 0.06s Refine Results
  1. 1
    Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia

    Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia by Mahesh Swaminathan, Jorge E. Cortes

    Published 2023-02-01
    Get full text
    Article
  2. 2
    Population modeling of bosutinib exposure‐response in patients with newly diagnosed chronic phase chronic myeloid leukemia

    Population modeling of bosutinib exposure‐response in patients with newly diagnosed chronic phase chronic myeloid leukemia by May Garrett, Beverly Knight, Jorge E. Cortes, Michael W. Deininger

    Published 2023-09-01
    Get full text
    Article
  3. 3
    Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial

    Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysi... by Jorge E. Cortes, Tara L. Lin, Kobby Asubonteng, Stefan Faderl, Jeffrey E. Lancet, Thomas Prebet

    Published 2022-10-01
    Get full text
    Article
  4. 4
    Therapy-related myelofibrosis does not appear to exist

    Therapy-related myelofibrosis does not appear to exist by Lucia Masarova, Gabriele Todisco, Taghi Manshouri, Kate J. Newberry, Jorge E. Cortes, Hagop M. Kantarjian, Zeev Estrov, Srdan Verstovsek

    Published 2017-06-01
    Get full text
    Article
  5. 5
    Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study

    Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study by Jorge E. Cortes, Jeff H. Lipton, Vamsi Kota, Fausto Castagnetti, Sarit Assouline, Tim H. Brümmendorf, Eric Leip, Andrea Viqueira, Carlo Gambacorti-Passerini

    Published 2023-07-01
    Get full text
    Article
  6. 6
    Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients

    Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients by Aref Al-Kali, Sergej Konoplev, Erpei Lin, Tapan Kadia, Stefan Faderl, Farhad Ravandi, Mohamad Ayoubi, Mark Brandt, Jorge E. Cortes, Hagop Kantarjian, Gautam Borthakur

    Published 2012-02-01
    Get full text
    Article
  7. 7
    Social determinants of health and upper gastrointestinal cancer outcomes in the United States: a systematic review

    Social determinants of health and upper gastrointestinal cancer outcomes in the United States: a systematic review by Brenda Santellano, Rashi Agrawal, Gabriela Duchesne, Muhannad Sharara, Gagan Agrawal, E. Andrew Balas, Meng-Han Tsai, Meng-Han Tsai, Asha Nayak, Jorge E. Cortes

    Published 2024-11-01
    Get full text
    Article
  8. 8
    Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

    Phase I study of sorafenib in patients with refractory or relapsed acute leukemias by Gautam Borthakur, Hagop Kantarjian, Farhad Ravandi, Weiguo Zhang, Marina Konopleva, John J. Wright, Stefan Faderl, Srdan Verstovsek, Sheela Mathews, Michael Andreeff, Jorge E. Cortes

    Published 2011-01-01
    Get full text
    Article
  9. 9
    A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy

    A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leu... by Gautam Borthakur, Herve Dombret, Philippe Schafhausen, Tim Henrik Brummendorf, Nicolas Boissel, Elias Jabbour, Mariangela Mariani, Laura Capolongo, Patrizia Carpinelli, Cristina Davite, Hagop Kantarjian, Jorge E. Cortes

    Published 2015-07-01
    Get full text
    Article
  10. 10
    Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

    Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies by Gautam Borthakur, Michael G. Rosenblum, Moshe Talpaz, Naval Daver, Farhad Ravandi, Stefan Faderl, Emil J. Freireich, Tapan Kadia, Guillermo Garcia-Manero, Hagop Kantarjian, Jorge E. Cortes

    Published 2013-02-01
    Get full text
    Article
  11. 11
    Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia

    Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia by Timothy P. Hughes, Pierre Laneuville, Philippe Rousselot, David S. Snyder, Delphine Rea, Neil P. Shah, David Paar, Elisabetta Abruzzese, Andreas Hochhaus, Jeffrey H. Lipton, Jorge E. Cortes

    Published 2019-01-01
    Get full text
    Article
  12. 12
    Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study

    Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study by Timothy P. Hughes, Giuseppe Saglio, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna Turkina, Shruti Kapoor, Ana Paula Cardoso, Becki Nieman, Sara Quenet, Jorge E. Cortes

    Published 2024-12-01
    Get full text
    Article
  13. 13
    Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN

    Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year res... by Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong-Wook Kim, Jerald Radich, Michael Savona, Patricia Martin-Regueira, Oumar Sy, Giuseppe Saglio

    Published 2024-05-01
    Get full text
    Article
  14. 14
    Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia

    Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia by Iman Abou Dalle, Ronald Paranal, Jabra Zarka, Shilpa Paul, Koji Sasaki, Wen Li, Jing Ning, Nicholas J. Short, Maro Ohanian, Jorge E. Cortes, Elias J. Jabbour, Ghayas C. Issa

    Published 2020-12-01
    Get full text
    Article
  15. 15
    Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia – a propensity score analysis

    Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia – a propensity score analysis by Koji Sasaki, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Koichi Takahashi, Marina Konopleva, Gautam Borthakur, Guillermo Garcia-Manero, William Wierda, Naval Daver, Preetesh Jain, Toshihisa Satta, Sherry Pierce, May Beth Rios, Jorge E. Cortes

    Published 2016-08-01
    Get full text
    Article
  16. 16
    Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy

    Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge E. Cortes, Zi Chen, Lan Zheng, Yan Li, Shi Bai, Pei Lin, Roberto N. Miranda, Jeffrey L. Jorgensen, Timothy J. McDonnell, Wei Wang, Hagop M. Kantarjian, Shimin Hu

    Published 2017-12-01
    Get full text
    Article
  17. 17
    Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring

    Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring by Rajyalakshmi Luthra, Keyur P. Patel, Neelima G. Reddy, Varan Haghshenas, Mark J. Routbort, Michael A. Harmon, Bedia A. Barkoh, Rashmi Kanagal-Shamanna, Farhad Ravandi, Jorge E Cortes, Hagop M Kantarjian, L. Jeffrey Medeiros, Rajesh R. Singh

    Published 2014-03-01
    Get full text
    Article
  18. 18
    Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study

    Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study by Carlo Gambacorti-Passerini, Jorge E. Cortes, Jeff H. Lipton, Hagop M. Kantarjian, Dong-Wook Kim, Philippe Schafhausen, Rocco Crescenzo, Nathalie Bardy-Bouxin, Mark Shapiro, Kay Noonan, Eric Leip, Liza DeAnnuntis, Tim H. Brümmendorf, H. Jean Khoury

    Published 2018-08-01
    Get full text
    Article
  19. 19
    A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors

    A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors... by Alejandro Zulbaran‐Rojas, Huei‐Kan Lin, Qiuling Shi, Loretta A. Williams, Binsah George, Guillermo Garcia‐Manero, Elias Jabbour, Susan O’Brien, Farhad Ravandi, William Wierda, Zeev Estrov, Gautam Borthakur, Tapan Kadia, Charles Cleeland, Jorge E. Cortes, Hagop Kantarjian

    Published 2018-11-01
    Get full text
    Article
  20. 20
    The intersection of melanoma survival and social determinants of health in the United States: A systematic reviewCapsule Summary

    The intersection of melanoma survival and social determinants of health in the United States: A systematic reviewCapsule Summary by McKenzie E. Maloney, BS, Caleb Bacak, BS, Kellen Tjioe, DDS, MSc, PhD, Loretta S. Davis, MD, E. Andrew Balas, MD, PhD, Gagan Agrawal, MS, PhD, Jorge E. Cortes, MD, Marisol Miranda-Galvis, DDS, MS, PhD

    Published 2024-12-01
    Get full text
    Article

Search Tools: